Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2015

01.04.2015 | case report

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in a myeloma patient with terminal renal failure and hepatitis C with high viral load

verfasst von: Priv. Doz. Dr. Niklas Zojer, Michael Gschwantler, Wolfgang Hilbe

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

We report on a patient with multiple myeloma and light-chain induced renal failure, diagnosed with hepatitis C and high viral load in the pre-transplant period. We show that the new hepatitis C virus directed drugs daclatasvir and sofosbuvir can be safely applied concomitantly to high-dose therapy with autologous hematopoietic stem cell transplantation. Liver enzymes remained in the normal range during the transplant and in the post-transplant period.
Literatur
1.
Zurück zum Zitat Locasciulli A, Bruno B, Alessandrino EP, et al. Italian Cooperative Group for Blood and Marrow Transplantation. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant. 2003;31(4):295–300. CrossRefPubMed Locasciulli A, Bruno B, Alessandrino EP, et al. Italian Cooperative Group for Blood and Marrow Transplantation. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant. 2003;31(4):295–300. CrossRefPubMed
2.
Zurück zum Zitat Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21. CrossRefPubMed Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21. CrossRefPubMed
3.
Zurück zum Zitat St Bernard R, Chodirker L, Masih-Khan E, et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant. 2015;50(1):95–9. St Bernard R, Chodirker L, Masih-Khan E, et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant. 2015;50(1):95–9.
4.
Zurück zum Zitat Raab MS, Breitkreutz I, Hundemer M, et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica. 2006;91(11):1555–8. PubMed Raab MS, Breitkreutz I, Hundemer M, et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica. 2006;91(11):1555–8. PubMed
5.
Zurück zum Zitat Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9(3):156–66. CrossRefPubMed Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9(3):156–66. CrossRefPubMed
6.
Zurück zum Zitat Zschiedrich S, Fischer R, Schmitt-Gräff A, Blum H, Breidert M. Acute hepatitis after autologous stem cell transplantation and rapid progression to liver cirrhosis. Eur J Gastroenterol Hepatol. 2010;22(9):1141–4. CrossRefPubMed Zschiedrich S, Fischer R, Schmitt-Gräff A, Blum H, Breidert M. Acute hepatitis after autologous stem cell transplantation and rapid progression to liver cirrhosis. Eur J Gastroenterol Hepatol. 2010;22(9):1141–4. CrossRefPubMed
7.
Zurück zum Zitat Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet. 1996;347(8994):92–3. CrossRefPubMed Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet. 1996;347(8994):92–3. CrossRefPubMed
8.
Zurück zum Zitat Ljungman P, Locasciulli A, de Soria VG, et al. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant. 2012; 47(9):1217–21. CrossRefPubMed Ljungman P, Locasciulli A, de Soria VG, et al. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant. 2012; 47(9):1217–21. CrossRefPubMed
9.
Zurück zum Zitat Peffault de Latour R, Lévy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004; 103(5):1618–24. CrossRefPubMed Peffault de Latour R, Lévy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004; 103(5):1618–24. CrossRefPubMed
Metadaten
Titel
High-dose chemotherapy and autologous hematopoietic stem cell transplantation in a myeloma patient with terminal renal failure and hepatitis C with high viral load
verfasst von
Priv. Doz. Dr. Niklas Zojer
Michael Gschwantler
Wolfgang Hilbe
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0198-4

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe